MedPath

A Prospective, Multicenter, European Registry Investigating the Lutonix Paclitaxel-Coated Balloon for the Treatment of In-Stent Restenosis within Bare-Metal Stents

Phase 2
Completed
Conditions
restenotic lesions - stenosis
10011082
Registration Number
NL-OMON33458
Lead Sponsor
utonix
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Not specified
Target Recruitment
20
Inclusion Criteria

Target lesions is in a native coronary with previous single bare metal stent
Stenosis is >50% and <100% by visual estimate or QCA prior to defined pre-dilatation

Exclusion Criteria

History of MI or thrombolysis within 72 hours of randomization
History of previous target vessel perforation
Angiographic evidence of thrombus or dissection within the target vessel

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
<p>Percent (%) Diameter Stenosis (DS) in the Analysis Segment at 6 months</p><br>
Secondary Outcome Measures
NameTimeMethod
<p>Clinical (at 1, 6, 12 & 24 months)<br /><br><br /><br>- Ischemia-driven target vessel revascularization (ID-TVR) defined as targe<br /><br>vessel diameter of at least 50% by Quantitative Coronary Analysis (QCA) with<br /><br>either ECG changes at rest or a positive functional study in the distribution<br /><br>of the target vessel, or stenosis of at least 70% irrespective of symptoms.<br /><br>- Ischemia-driven target lesion revascularization (ID-TLR)<br /><br>- Composite of cardiac death, myocardial infarction, and ID-TLR<br /><br>- Composite of cardiac death, myocardial infarction and target vessel<br /><br>revascularization TVR<br /><br>- Procedural success<br /><br>- Device success</p><br>
© Copyright 2025. All Rights Reserved by MedPath